Occlusive cerebrovascular disease leads to brain ischemia that causes neurological deficits.
Here we introduce a new strategy combining mesenchymal stromal cells (MSCs) and ex …

Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic
immunotherapy designed to selectively replicate within tumors and produce granulocyte …

Abstract In this White Paper, we discuss the current state of microbial cancer therapy. This
paper resulted from a meeting ('Microbial Based Cancer Therapy') at the US National …

Purpose: To conduct a phase I clinical trial with a second-generation oncolytic herpes
simplex virus (HSV) expressing granulocyte macrophage colony-stimulating factor (Onco …

Highlights•Viruses have been suggested as anti-cancer agents since the early 20th
century.•An overview of developments since the 1990s is provided.•The first successful …

Many therapeutic interventions using neurotrophic factors or pharmacological agents have
focused on secondary degeneration after spinal cord injury (SCI) to reduce damaged areas …

Overexpression of the gene encoding the 70-kDa heat shock protein (hsp70) has previously
been shown to protect neuronal cells against subsequent thermal or ischemic stress. It has …

Background Oncolytic viruses preferentially replicate in tumors as compared to normal
tissue and promote immunogenic cell death and induction of host systemic anti-tumor …

Background and Purpose—Fibroblast growth factor-2 (FGF-2) administration and bone
marrow stromal cell (MSC) transplantation could improve neurological deficits after …

Several lines of evidence suggest that dendritic cells (DCs), the most potent antigen-
presenting cells known, play a role in the immunological control of herpes simplex virus …